Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neurogenic Orthostatic Hypotension Clear all

Conditions: Hypotension, Orthostatic
Interventions: Midodrine hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 19 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Fort Wayne, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 8 more

Conditions: Neurogenic Orthostatic Hypotension
Interventions: Sinosuidal Galvanic Vestibular Stimulation, Placebo; Device
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa capsules, Placebo capsules; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 168
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more

Conditions: Spinal Cord Injuries, Autonomic Imbalance, Autonomic Dysreflexia, Orthostatic; Hypotension, Neurogenic
Interventions: Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia, Transcutaneous spinal cord stimulation; Diagnostic Test · Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 30 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions: Droxidopa, Placebo; Drug
Lead sponsor: William Ondo, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions: Placebo, Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Orthostatic Hypotension
Interventions: Inspiratory Threshold Device (Res-Q-Gard ITD), Sham Inspiratory Threshold Device; Device
Lead sponsor: Alfredo Gamboa; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 23
States / cities: Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more

Conditions: Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Supine Hypertension, Neurogenic Orthostatic Hypotension
Interventions: Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position; Device · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
Interventions: Northera, Placebo; Drug · Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
Interventions: ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more

Conditions: Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions: Droxidopa, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 44
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more

Conditions: Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions: TD-9855, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 40 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more

Conditions: Hypotension, Orthostatic
Interventions: Midodrine Hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1999
U.S. locations: 15
States / cities: Huntsville, Alabama • Miramar, Florida • St. Petersburg, Florida + 12 more

Conditions: Parkinson Disease, Falls Patient
Interventions: Droxidopa, Placebo; Drug · Other
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 30 Years to 83 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Neurogenic Orthostatic Hypotension
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: ampreloxetine; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more

Conditions: Hypotension, Orthostatic
Interventions: midodrine hydrochloride (ProAmatine®); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: St. Petersburg, Florida • Upland, Pennsylvania • San Antonio, Texas

Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions: Ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions: Placebo, Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more

Conditions: Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
Interventions: Midodrine, Placebo pill, Abdominal compression, sham compression; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more

Search by objective public record fields.

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension

Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Breathing Device for Orthostatic Hypotension (OH)

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

CPAP for the Treatment of Supine Hypertension

Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

A Study for Patients With Neurogenic Orthostatic Hypotension

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension